Lung cancer patient gets a new therapy option 

Patient Profile

• 77-year-old male with metastatic lung cancer

•  No biomarker present, so the patient was limited to regular chemotherapy options.

Travera Testing

• Tumor cells were isolated from a malignant pleural effusion specimen.

• Travera measured the mass response of the patient’s cancer cells to two cancer drugs, carboplatin and etoposide

• Testing showed cells responded to both chemotherapies. 

Results

• Oncologist put the patient on a three-drug combination: carboplatin, etoposide, and the checkpoint inhibitor atezolizumab. 

• Patient responded to the treatment, as indicated by the reduction of his pleural effusion.